The present invention relates to sustained release antimicrobial cannulas or catheters, which are either implantable or insertable into a human body. These devices have an antimicrobial agent incorporated within the device, which diffuses out in situ to prevent the proliferation or colonization of microbes in regions adjacent to the exterior of the cannula or catheter. The present invention also relates to methods for making the same, products made by these methods, and methods of using the sustained release antimicrobial cannulas or catheters, to prevent proliferation, colonization or continued viability of a microbial population in regions adjacent to the exterior of the respective cannula or catheter.
Most catheters are a cannula or tube like device which is inserted into a portion of a person's body in order to transport fluids or gases in or out of that particular portion of the body. In passing through any particular portion of the body in order to reach its destination, the catheter will come into contact with various tissues in the body. For example, a catheter used to drain ones bladder (such as a “Foley” catheter) must pass through the urethral tract in order to reach the bladder. A nasogastric catheter must pass through the nasal passageway and the esophagus in order to reach the stomach. Some catheters, such as these, are inserted through existing passageways in order to reach their destinations, while others are inserted through surgically created passageways.
In virtually every catheterization, there is a significant potential for microbial growth along the exterior surface of the catheter which can lead to serious infections such as urinary tract infections, bladder infections and the like. Such an infection can be encouraged when adjacent tissues are inflamed due to irritation from rubbing or chafing against this catheter. This is because inflamed or irritated tissues may be less apt to respond effectively to suppress local microbial infections. In such a situation the infection can spread and intensify, placing the patient at further risk. Such infections can lead to sepsis of the bladder particularly in elderly patients who are incontinent and have a chronic need for catheterization with an indwelling self-retaining catheter such as a “Foley” catheter. Long-term use of indwelling urinary catheters in nursing home patients is well known as a potential cause of significant morbidity due to such infections.
This problem is widely recognized and many solutions for this problem have been suggested in the past. None of these solutions, however, have been completely free of secondary complications and/or completely successful in eliminating the problem. For instance, systemic use of antimicrobial drugs or agents has been tried. However, these drugs generally have undesirable secondary effects upon the patient when used systemically, especially when there is a chronic need for catheterization and the drug must be employed for a long period of time. Local use of such drugs or agents can be effective for a short period of time, but has not been found to be effective for long-term use for a number of reasons. First, the drug or agent is easily washed out if there is a leakage of urine through the urinary tract outside of the catheter. Second, the drug or agent may be delivered only to certain areas of the urinary tract and, third, the drug or agent may be absorbed by the body tissues adjacent to the catheter and transported elsewhere within the body.
Other methods of preventing periurethral contamination have been suggested. These include careful cleansing of the periurethral area on a routine basis, impregnating a sponge or the like with an antiseptic solution and retaining it in a position proximate the urethral area, applying antimicrobial ointments to an external portion of the urinary tract, intraurethral irrigation of the urinary tract through a separate channel, lubrication of the catheter with an antimicrobial-containing material and the use of catheters impregnated with antimicrobial agents. Each of these methods has been explored and none have been found to be entirely satisfactory. In vitro tests of impregnated catheters indicate that the antimicrobial agents within the catheters have a tendency to leach or diffuse out of the catheters in a short period of time. Often, the antimicrobial activity was either gone or markedly diminished within 24 to 48 hours of insertion within the urethral tract. Therefore, it would be appreciated that a sustained release antimicrobial cannula or catheter is needed in order to address the needs of patients requiring long-term catheterization or the like.
Accordingly, it will be appreciated that there is a need for a medical device, cannula or catheter which will address these and other problems associated with the prior art devices. The present invention provides advantages over the prior art cannulas and catheters, over the prior art methods for manufacturing the same, and also offers other advantages over the prior art and solves other problems associated therewith.
Accordingly, a sustained release antimicrobial cannula for residence within a portion of a human body through which aqueous biological fluids can pass is provided. The sustained release antimicrobial cannula comprises a tube having an inner surface, defining an internal lumen, and an outer surface. The tube has a polymeric matrix and an antimicrobial agent residing within at least a portion of the polymeric matrix, wherein the polymeric matrix can include cured silicon rubber.
The antimicrobial agent can, for example, be a finely divided nitrofuran such as nitrofurazone, a finely divided paraben antifungal (e.g., methyl paraben, ethyl paraben, or propyl paraben), or combinations thereof. Such antimicrobial agent is soluble in water and is effective to prevent proliferation of certain microbes in an otherwise growth supporting aqueous environment when dissolved in the aqueous environment to the limit of its solubility therein at 37° C. In an embodiment, the antimicrobial agent has a solubility of about 0.5% by weight or less in water at a pH of about 6 and a temperature of about 25° C.
The antimicrobial agent can diffuse out of the polymeric matrix and into an aqueous biological environment when the polymeric matrix comes into contact with such an aqueous biological environment. In an embodiment, at least a finite portion of the polymeric matrix proximate the outer surface includes an amount of from about 10 to about 60% by weight of the antimicrobial agent, and the antimicrobial agent in the finite portion of the polymeric matrix and the solubility of the antimicrobial agent cooperate to provide a potential for sustained release diffusion of the antimicrobial agent into the aqueous biological fluids within the human body, during normal therapeutic use of the cannula therein, so long as the aqueous biological fluids are not saturated with the antimicrobial agent, such that the antimicrobial agent within the finite portion of the polymeric matrix can continue to diffuse into the aqueous biological fluids within the human body in an amount effective to prevent proliferation of certain microbes immediately adjacent to the cannula in aqueous biological environments for a period of not less than about three weeks. In certain embodiments the cannula is a urinary catheter for residence within a urinary tract, for example a “Foley” catheter having an expandable balloon cavity, a second lumen in communication with the expandable balloon cavity and a coating on at least a portion of the exterior surface of the catheter proximate the balloon cavity which is for example a cured silicon rubber polymeric matrix incorporating an antimicrobial agent capable of diffusing out of the polymeric matrix in aqueous environments. In an embodiment, the rate of diffusion of the antimicrobial agent from the polymeric matrix can increase when the expandable balloon portion expands.
It is an embodiment, the present invention provides a sustained release antimicrobial cannula or catheter which can be used on a long-term basis to reduce or eliminate the incidence of urinary tract infections in patients having a chronic need for catheterization. The present invention provides a catheter having a large percentage of active antimicrobial agent incorporated into a cured silicon rubber outer coating.
In an embodiment, the antimicrobial agent is a finely divided nitrofuran compound such as nitrofurazone having a solubility of about 0.2% by weight or less, a paraben antifungal (e.g., methyl paraben, ethyl paraben, or propyl paraben), or combinations thereof. In an embodiment the mean particle size of the antimicrobial agent particles is about 200 microns or less in order to create a very smooth outer surface on the cannula or catheter. This is important to reduce the incidence of irritation of the tissues within the urinary tract. It will be appreciated that it can be difficult to incorporate a large percentage of solid antimicrobial agent within a polymeric matrix and still provide a smooth outer surface, as well as sufficient flexibility and durability so as to be suitable for the intended use. In certain embodiments of the present invention the mean particle size of the antimicrobial agent particles is about 100 microns or less enabling the incorporation of this agent at an even higher percentage in the polymeric matrix, while still retaining the desired smoothness, flexibility and durability of the outer coating.
In the drawings, in which like and primed, reference numerals indicate corresponding parts throughout the several views,
a, 20b and 20c are flow charts representing certain steps in accordance with the present invention;
a, 42b and 42c are flow charts illustrating certain steps in methods in accordance with the present invention;
Referring now generally to the drawings, and specifically to the cannulas and catheters 4, 5 shown in
The antimicrobial agent utilized in the invention can be utilized to inhibit or kill microbes such as bacteria, fungi, and/or viruses and for example inhibit or kill at least bacteria and fungi. An antimicrobial agent is a compound, drug or composition containing a compound or drug that inhibits the growth of or kills one or more microbes, such as bacteria, fungi, and/or viruses. In an embodiment, the antimicrobial agent is utilized to inhibit the growth of or kill bacteria and fungi, and are therefore referred to as antibacterial and antifungal agents. In an embodiment, an antimicrobial agent is an antibacterial agent, an antifungal agent, or combinations thereof.
In an embodiment, the antimicrobial agent includes an antibacterial and an antifungal agent. For example, the antibacterial agent and the antifungal agent can be a nitrofuran compound and a paraben antifungal (e.g., methyl paraben, ethyl paraben, or propyl paraben), respectively. In an embodiment, the antibacterial agent is nitrofurazone and the antifungal agent is a paraben antifungal (e.g., methyl paraben, ethyl paraben, or propyl paraben).
The nitrofuran compounds utilized in the invention have the formula below:
Where R is a carbon continuing moiety such as that disclosed, for example, in K. Miura et al., entitled “The Nitrofurans,” in Progress in Medicinal Chemistry (Vol. 5), pp. 320-381, (G. P. Ellis & G. B. West (eds.), Plenum Press, New York, N.Y. (1967), the disclosure of which is incorporated by reference herein. Suitable nitrofurans are those which are soluble in water and have antimicrobial activity in aqueous environments.
Suitable nitrofuran compounds include nitrofurantoin, nitrofurazone, nidroxyzone, nifuradene, furazolidone, furaltidone, nifuroxime, nihydrazone, nitrovin, nifurpirinol, nifurprazine, nifuraldezone, nifuratel, nifuroxazide, urfadyn, nifurtimox, triafur, nifurtoinol, nifurzide, nifurfoline, nifuroquine, and derivatives of the same, and other like nitrofurans which are both soluble in water and possess antibacterial and antimicrobial activity. References to each of the above cited nitrofuran compounds may be found in the Merck Index, specifically the ninth edition (1976) and the eleventh edition (1989) thereof, published by Merck & Co., Inc., Rahway, N.J., the disclosures of which are each incorporated herein by reference. It will be appreciated that suitable nitrofuran compounds include nitrofuran compounds which are medically acceptable for topical use, for example topical use for mucosal surfaces.
In an embodiment, the nitrofuran compounds have a solubility of about 0.2% by weight or less in water at a pH of about 6 and temperature of about 25° C. In an embodiment, the nitrofuran compounds have a solubility in water of about 0.2 to about 0.001% by weight in water at a pH of about 6 and a temperature of about 25° C. In an embodiment, the solubility of the nitrofuran compound under these conditions is about 0.1% by weight or less.
It will be appreciated that it is important to have an antimicrobial agent which is effective to prevent the proliferation and colonization of microbes within aqueous systems, and that it is also important to have an antimicrobial agent which is not so soluble in aqueous systems that it will immediately diffuse out of the polymeric matrix within which it is incorporated. These characteristics are important in order to provide a sustained release of the antimicrobial agent into the aqueous systems so as to provide for long-term antimicrobial activity. It will also be appreciated that the rapid release or diffusion of the antimicrobial agent into an aqueous environment in contact with the outer antimicrobial release layer 61 will also result in irregularities in the surface of the catheter or cannula 4, 5 which may irritate adjacent tissues within the patient's urinary tract.
It will be further appreciated that it is important that the outer surface of the outer antimicrobial release layer 61 is smooth so as to minimize the incidence of irritation to the tissues of the urinary tract. In order to provide a smoother outer surface, it is important to minimize the particle size of the finely divided antimicrobial agent particles incorporated into the outer antimicrobial release layer 61. The mean particle diameter of the antimicrobial agent particles is for example about 200 microns or less, about 150 microns or less, or about 100 microns or less. The size of the mean particle diameter can be controlled by filtering the larger particles out of the mixture used to coat the intermediate tubes used to make the finished catheters or cannulas 4, 5.
In certain embodiments of the present invention, the outer antimicrobial release layer 61 includes silicone fluid which is incorporated therein to provide for more rapid diffusion of the antimicrobial agent upon exposure to an aqueous medium. It is believed, but not relied upon, that the silicone fluid allows the cured silicone polymeric matrix to provide for greater diffusion of aqueous media into and out of the polymeric matrix. In addition, the silicone fluid is desirable because it provides a softer, more pliable polymeric matrix which is also easier to elongate. It is further believed that the incorporation of the silicone fluid along with the minimization of the mean particle diameter of the antimicrobial agent particles cooperate to maximize the smoothness of the outer surface of the outer antimicrobial release layer 61, and to maximize the structural integrity, softness and stretchability of the release layer 61. The structural integrity is also important so that the amount of the antimicrobial agent incorporated into the release layer 61 can be maximized. It will be appreciated that the greater the structural integrity of the polymeric matrix, the less the matrix will break down and disintegrate. If the release layer attached to the catheter or cannula 4, 5 disintegrates or flakes off for lack of better bonding, the product will be unacceptable in the marketplace. Although it is believed that the most important factor in this regard is the small particle size, it is also important to incorporate some silicone fluid to soften the polymeric matrix and allow it to be more stretchable, thereby minimizing the rigidity of the polymeric matrix. Although it is possible to use antimicrobial agent particles of virtually any size, it will be appreciated that suitable mean particle diameters include less than about 500 microns, about 400 microns or less, about 300 microns or less, or about 200 microns or less, to be able to incorporate more of the agent into the polymeric matrix and still have a soft and pliable polymeric matrix and a smooth outer surface so as to provide commercially acceptable products.
In certain embodiments of the present invention, the outer antimicrobial release layer 61 for example includes about 2-80% by weight, about 5-70% by weight, about 10-60% by weight, or about 15-55% by weight of the antimicrobial agent in the present invention.
The outer antimicrobial release layer 61 may also include an anti-inflammatory agent in amounts similar to the amounts recited herein for the antimicrobial agent. Suitable anti-inflammatory agents are water soluble, anti-inflammatory agents such as hydrocortisone, hydrocortisone acetate, hydrocortisone phosphate, hydrocortisone hemisuccinate sodium salt, hydrocortisone tebutate, and the like. In this regard, it will be appreciated that any therapeutically acceptable, water soluble anti-inflammatory agent may be used in the present invention in order to reduce inflammation of the tissues adjacent to the present catheter or cannula 4, 5 when inserted in a human body. In an alternate embodiment of the present invention, the hydrocortisone compound has a solubility in water of less than about 0.1% by weight.
In order to provide long-term sustained release antimicrobial activity, the present catheter or cannula 4, 5 for example provides an outer antimicrobial release layer 61 having a smoother outer surface such that it minimizes irritation to adjacent tissues. This release layer 61 for example includes about 10-60% by weight of a suitable antimicrobial agent having a mean particle diameter of 200 microns or less. In an embodiment, the catheter or cannula 4, 5 of the present invention provides a potential for sustained release of the antimicrobial agent incorporated in the outer antimicrobial release layer 61 for a period of at least about two weeks, for example at least about three weeks, at least about four weeks, or about five weeks. In further embodiments, the antimicrobial agent is released for periods of at least about six weeks, seven weeks, eight weeks, or more, depending upon the amount of the solid antimicrobial agent which is incorporated into the release layer 61 and the solubility thereof in water. It will be appreciated, however, that although it is desirable to incorporate a large amount of the antimicrobial agent into the release layer 61, it is also important to retain the elongation characteristics and smoothness which is generally available to cellastic membranes used on similar catheters or cannulas.
It will be appreciated that the rate of release of the antimicrobial agent into the surrounding aqueous environment is dependent on the rate of fluid exchange. It has been observed that 3 milliliters of fluid exchange generally occurs within an average female urinary tract every 24 hours. Because the concentration of the antimicrobial agent in the fluid adjacent to the release layer 61 will generally reach a point of equilibrium with the antimicrobial agent within the release layer 61, the diffusion rate of the antimicrobial agent out of the release layer 61 will be slowed as the concentration reaches maximum solubility for the particular antimicrobial agent incorporated into the release layer 61. As additional fluid passes into the urinary tract and dilutes the fluid already present or washes the fluid out, the diffusion rate will increase. In this way, the present invention is designed to attempt to maintain a concentration of the antimicrobial agent in the aqueous fluids within the urethra at a level generally commensurate with the maximum solubility of the antimicrobial agent. It will be appreciated, however, that this will not always be the case. Therefore, it is also important to provide a burst of antimicrobial agent in the urethra upon insertion of the catheter or cannula 4, 5 so as to immediately eliminate the presence of viable microbes therein. This is accomplished when a Foley catheter 4, 5 such as that shown in
In an embodiment, nitrofurazone is the nitrofuran compound of choice and a paraben antifungal (e.g., methyl paraben, ethyl paraben, or propyl paraben) is the antifungal of choice. When using nitrofurazone, it is desirable to maintain a nitrofurazone concentration in aqueous fluids adjacent to the catheter at about 0.02% by weight in order to minimize and for example eliminate antimicrobial proliferation within the urinary tract.
When using a paraben antifungal (e.g., methyl paraben, ethyl paraben, or propyl paraben)™, it is desirable to maintain a paraben concentration in aqueous fluids adjacent to the catheter at about 0.05 to 0.10% by weight. In an embodiment, from 0.075 to 0.10% by weight. In an embodiment about 0.085% by weight.
It will be appreciated that nitrofurazone is desirable, not only because of its limited solubility in water, but also because of its broad antibacterial and antimicrobial activity in respect to both Gram positive and Gram negative microbes which commonly infect the bladder and the urinary tract. Nitrofurazone is also desirable because of its yellow color, which provides an attractive product for commercial presentation. In addition, both nitrofurazone and paraben antifungal (e.g., methyl paraben, ethyl paraben, or propyl paraben) appear to stand up relatively well to the high temperatures used to cure the silicone rubber within the release layer 61 during processing.
In certain embodiments, a silicone rubber/nitrofurazone/paraben dispersion or mixture is prepared as follows: 100 grams of nitrofurazone powder and 400 grams paraben is wetted with approximately 10 fluid ounces of 1,1,1-trichloroethane (Hydrite Chemical Co., LaCrosse, Wis.). This mixture is agitated vigorously. In a separate container, 100 grams of uncured silicone rubber (2 parts platinum cure system, ½ part A and ½ part B (Dow Corning, Midland, Mich.)) is dispersed with about 20 grams of silicone fluid (360 fluid, 20 centistoke (Dow Corning, Midland, Mich.)) in a ratio of 5 parts to 1 in approximately 10 fluid ounces of 1,1,1-trichloroethane (Hydrite Chemical Co., LaCrosse, Wis.). Another 30 fluid ounces of 1,1,1 trichloroethane is added to the nitrofurazone/paraben/trichloroethane mixture, and agitated continuously. The nitrofurazone/paraben/trichloroethane mixture is passed through a filter to remove the larger nitrofurazone and paraben particles. In an embodiment, two 6-inch cone-shaped filters from TUFCO (medium mesh) are used back-to-back (one inside the other) to filter the nitrofurazone/paraben/trichloroethane mixture. The filtering step is repeated three or four times to remove the larger, oversized particles of nitrofurazone and paraben which will not pass through the medium mesh TUFCO filters. When the larger particles have been removed, the nitrofurazone/paraben/trichloroethane mixture or dispersion is combined with the silicone rubber dispersion and agitated constantly. In an embodiment, the fluid mixture of the solid nitrofurazone and paraben particles in the silicone rubber dispersion is allowed to settle just prior to dipping to form the release layer 61 on the outer surface of the overcoat layer 44 as further discussed herein below. It will be appreciated that the dispersion may be pumped through a single filter or a series of filters designed to provide a nitrofurazone/paraben dispersion having a precise mean particle diameter.
Referring now more specifically to the drawings, and specifically to
Referring now also to
Referring now also to
Referring now also to
When the intermediate tubes 3 have been secured on the support rods 26, the pallet 24 can be transferred from place to place, and the intermediate tubes 3 on the pallet 24 can be dipped in a series of baths (see
The first step in the automated coating or dipping process of forming the balloon portion 32 of the balloon catheter 4 (shown in
When the intermediate tubes 3 are removed from this first bath 33a of removable bond preventing agent, the agent adheres to the outer surface 14 of the intermediate tube 3, and enters the capillary lumen access opening 12 and runs up into the capillary lumen 6. In one embodiment the agent is petrolatum, which is heated to about 140°-160° F., for example about 150° F. At these temperatures, the petrolatum will run up into the capillary lumen 6 through the capillary lumen access opening 12 with the assistance of the “capillary effect”, which draws the fluid into the capillary lumen 6 to the level of the petrolatum in the first tank 33. As the intermediate tubes 3 are withdrawn from the hot petrolatum, petrolatum on each tube cools and solidifies to form a semi-solid coating 38 on the outer surface 14 and a semi-solid filling 34 in the capillary lumen 6 and the capillary lumen access opening 12 which cooperate to plug the capillary lumen access opening 12. In an alternate embodiment, the bond preventing agent in the first tank 33 is liquid soap at room temperature (about 62°-74°). When the tubes 3 are withdrawn from the first dip tank 33, the liquid soap forms of semi-solid just as the hot petrolatum did as it cooled. Although both of these bond preventing agents are effective, there is some advantage to using the soap because it does not require the added expense for heating. Furthermore, it is believed soap is easier to remove from the capillary lumen 6 and the balloon cavity 54.
After the intermediate tubes 3 are coated and the capillary lumen access openings 12 are plugged simultaneously with bond preventing agent in this manner (see
In subsequent steps, the proximal end 30 of the balloon catheter 4 is secured to an end piece 46 to form a completed Foley catheter 5 (shown in
The completed Foley catheter 5 also includes a fluid conduit access opening 56 in an exterior surface 63 of the completed Foley catheter 5. The fluid conduit access opening 56 communicates with the fluid conduit lumen 8. In certain embodiments, the access opening 56 is punched into the catheter 5 following the curing steps. In an embodiment, two access openings 56, one on either side of the catheter 5 (second access opening 56 not shown) are punched into the catheter 5. In an alternate embodiment (not shown), the access opening 56 is created before the intermediate tube 4 is dipped in the silicone antimicrobial coating mixture (silicone/nitrofuran/paraben compound fluid mixture). In this embodiment, an inner surface layer (not shown), incorporating the fungicide agent 15 is created along an inside of the fluid conduit lumen 8.
In certain methods in accordance with the present invention, the end piece 46 is made by a process of injection molding. In an embodiment, the proximal end 30 of the balloon catheter 4 is inserted into the injection molding apparatus after the overcoat layer 42 and the release layer 61 have been cured. The polymeric bonding composition, for example silicone rubber, is then injected into the mold (not shown) and the end piece 46 is molded onto the proximal end 30 of the balloon catheter 4 to make the completed Foley catheter 5 shown in
In order to test the integrity of the completed catheter 5, prior to engaging the plug 50 in the proximal capillary lumen access opening 52 in the end piece 46, the proximal capillary lumen access opening 52 is slipped over a hot water nozzle (not shown), and a measured amount of a hot aqueous solution, for example water or water containing a trace of surfactant, at a temperature of between about 120°-160° F., for example about 140° F., is pumped into the capillary lumen 6 from a standard hot water heater (not shown) by a commercially available water pump (not shown) such that the balloon portion 58 is expanded. The balloon portion 58 of the overcoat layer 42 is the portion of the overcoat layer 42 which is not bonded to the outer surface 14 of the intermediate tube 3. The balloon portion 58 of the overcoat layer 42 cooperates with the portion 14c of the outer surface 14 which remained coated with the bond preventing agent prior to the step of dipping the intermediate tube 3 in the polymeric bonding composition, to define a balloon cavity 54. The balloon cavity 54 communicates with the capillary lumen 6 via the capillary lumen access opening 12. When the hot water solution is pumped or injected into the capillary access lumen 6 to test the completed catheter 5 and the balloon portion 58, the balloon portion 58 and the balloon cavity 54 are expanded. If there is a significant lack of integrity in the balloon portion 58 it will be exposed when the water is introduced in this manner. In addition to testing the balloon portion 58, the water solution will also remove the remaining bond preventing agent in the balloon lumen 54 and the capillary lumen 6 when it is removed. Although some of the bond preventing agent may come out of the capillary lumen 6 via the proximal capillary lumen access opening 52 during the step of curing the overcoat layer 42, the hot aqueous solution is generally believed to remove most of the bond preventing agent, although a residue may remain.
Following the preliminary test, which relies on a visual observation to determine whether there is any lack of integrity, a further test is used to obtain further assurance that there are no leaks in the balloon portion 58. This further test is accomplished by engaging the proximal capillary lumen accessing opening 52 to the nozzle of a commercially available leak tester (not shown). One such device is a Model No. 6510 Caps Tester from Caps Himmelstein (Hoffman Estates, Ill. 60195). Once the completed catheter 5 is tightly secured over the nozzle, an electrical switch, such as a hand switch or, for example, a foot pedal, is used to release a measured blast of air into the capillary lumen 6. When the air is introduced into the capillary lumen 6 it also enters the balloon cavity 54 via the capillary lumen access opening 12 and inflates the balloon portion 58 and, thereby, expands the balloon cavity 54. The leak tester is designed to sense any loss of pressure once the balloon portion 58 is inflated, and will given an indication, therefore, if there are any measurable leaks. After this test is completed, the completed catheters 5 that have passed all tests, are then packaged, for example in a material which breathes such as Tyvek™ (from DuPont), and boxed. The boxes are then sterilized with ETO (ethylene oxide) and then stored for shipment.
In certain embodiments, balloon fabrication is almost completely automated. Entire sets of balloon catheters 4 are manufactured simultaneously. In an embodiment, pallet 24 has 400 spring steel support rods 26 attached to a pallet in 20 rows of 20 rods, wherein each of the rods 26 is about 1 inch from each adjacent rod. Double lumen tubing (not shown) is for example made by an extrusion process which is known to those of skill in the art. The tubes 2 are cut to length as the tubing leaves the extruder (not shown). An opening 12 is created in the outer surface 14, for example with a hollow drill bit or tube (not shown), so as to communicate with the capillary lumen 6. The distal portion 6a of the capillary lumen 6, located between the distal end 16 of the tube 2 and the capillary lumen access opening 12, is injected with a measured amount of a polymeric bonding composition, for example silicone rubber, so that the distal portion 6a is filled and sealed. A rounded tip 20 is for example formed at the distal end 16 of the double lumen tube 2 by inserting the tube 2 in a molding device (not shown).
In one embodiment of the present method, 400 of the intermediate tubes 3 are then mounted vertically on rigid spring steel support rods 26 on a pallet 24 in the manner previously described. The pallet 24 is then moved via a transporting mechanism 22 (see
(A) The pallet 24 is stopped over a first tank 33, which contains white USP petrolatum heated to about 67° C. (about 150° F.). The tank is raised so as to immerse the intermediate tubes 3 into the petrolatum to such a depth that the petrolatum reaches the proximal end of the desired balloon location. The dip tank 33 is then lowered and a portion of the outer surface 14 of the intermediate tubes 3 are coated with petrolatum. This portion extends from the point at which the proximal end of the balloon portion 58 will begin to the distal end of the tip 20 of the intermediate tube 3.
(B) The pallet 24 is then automatically advanced and stopped over a second dip tank 35 which contains white USP petrolatum heated to about 120° C. (about 250° F.). The second dip tank 35 is raised so as to immerse the intermediate tubes 3 into the super-heated petrolatum so that the super-heated petrolatum comes into contact with the petrolatum coating on outer surface 14 of the intermediate tube 3 from the prior dipping step up to a location where a distal end of the balloon portion 58 will end. The second dip tank 35 is then lowered. This dipping step causes the coating of petrolatum from the prior dipping step to be largely removed from a portion 14a of the outer surface 14 of the intermediate tube 3 from a location where the distal end of the balloon lumen 54 will be located (designated by dashed line B) to the distal end 20a of the tip 20 of the intermediate tube 3. Some residual petrolatum may remain on the outer surface 14 of the intermediate tube 3 in this portion 14a of the outer surface 14. However, most of the petrolatum is removed.
(C) The pallet 24 is then automatically advanced and stopped over a third dip tank 37 containing mineral spirits heated to about 200° F. The third dip tank 37 is then raised so as to immerse the intermediate tubes 3 into the mineral spirits to the same depth as they were immersed in the super-heated petrolatum in the second dip tank 35. The tank 37 is then lowered and all but a trace amount of the petrolatum is removed from the portion 14a of the outer surface 14 below the portion 14c of the outer surface 14, which will eventually be proximate the balloon lumen 54.
(D) The pallet 24 is then automatically advanced and stopped over a fourth dip tank 39 containing a volatile organic solvent such as toluene, trichloromethane or the like. The fourth tank 39 is then raised to immerse the intermediate catheters 3 to the same depth as previously immersed in the second and third tanks 35 and 37, thereby removing essentially all traces of the petrolatum from this portion 14a of the outer surface 14. The intermediate catheter tube 3 now has a band 38 of semi-solid petrolatum located around the axial circumference of the intermediate tube 3 in the location where the balloon cavity 54 will be created. The petrolatum not only coats the portion 14c of the outer surface 14 located in this area, but also fills a portion of the capillary lumen 6 and plugs the capillary lumen access opening 12, which will eventually be used to inflate the balloon portion 58 of the completed Foley catheter 5.
(E) The pallet 24 is then lowered and automatically advanced to a fifth dip tank 41 containing a low-solids hexamethyl disiloxane or toluene silicone rubber solution which is effective to minimize any disruption of the integrity of the petrolatum coating 38 remaining on the intermediate tube 3 proximate the portion 14c of the outer surface 14 where the balloon lumen 54 will be created during subsequent dipping steps. The fifth tank 41 is then raised to immerse essentially the entire length of the intermediate tube 3 in the solution. This step can be subsequently repeated at intervals, for example allowing time for significant solvent evaporation, either in the same tank or in a subsequent tank containing a greater concentration of silicone rubber, until the overcoat layer 42 and the balloon portion 58 of the overcoat layer 42 have a desired balloon thickness. The thickness over the overcoat layer 42 and the balloon portion 58 can be, for example, 17.5 thousandths of an inch (plus or minus 2.5 thousandths of an inch). The tank 41 is then lowered, and the overcoat layer 42 is allowed to dry and the solvent is allowed to evaporate for about 15 minutes, for example about 30 minutes or about an hour.
(F) The pallet 24 is advanced to a sixth dip tank 43 containing a silicone rubber/nitrofuran compound mixture or dispersion 17, and the tubes 3 are completely immersed again. The tank 43 is lowered. The pallet is then advanced through a drying area where solvents are allowed to evaporate, and then through a heat cure step, where the balloon catheters 4 formed by this process are cured at a temperature just below the boiling point of any solvent used in any of the silicone rubber dip solutions for an hour or two. For toluene this temperature is about 200°
(G) After the heat cure, the balloon catheters 4 are allowed to cool and are then removed from the support rods 26. The proximal ends 30 of each of the balloon catheters 4 is then inserted into an injection molding apparatus (not shown), which forms the end piece 46 of the completed Foley catheter 5.
(H) The completed Foley catheters 5 are then finished by punching a fluid conduit access opening 56 in the exterior surface 62 such that it communicates with the fluid conduit lumen 8 in a location below or distal to the balloon portion 58.
(I) The completed Foley catheters 5 are then sent through the test sequence described hereinabove, during which the balloon portion 58 of each completed Foley catheter 5 is inflated and the petrolatum band 38 within the balloon cavity 54 is largely removed. Referring now to
(A) Providing a tube having an outer surface and first and second lumens;
(B) Cutting the tube to a desired length;
(C) Creating a first lumen access opening in the outer surface to communicate with the first lumen;
(D) Filling the first lumen with a polymeric bonding composition up to the first lumen access opening from an end nearest the first lumen access opening;
(E) Sealing the end of the tube nearest the first lumen access opening; and
(F) Securing the tube to a movable pallet.
These steps are followed by the following steps:
(A) Simultaneously coating a first portion of the outer surface and plugging the first lumen access opening with a removable bond preventing agent;
(B) Stripping the coating of removable bond preventing agent away from a portion of the outer surface adjacent to the first portion;
(C) Coating the outer surface and the remaining coating of removable bond preventing agent with an overcoat layer of a suitable film forming polymeric bonding composition;
(D) Coating the overcoat layer with a silicone rubber/antimicrobial coating mixture to form an outer antimicrobial release layer;
(E) Air drying outer antimicrobial release layer; and
(F) Curing the overcoat layer and the outer antimicrobial release layer.
Following those steps, methods of the present invention include the following steps:
(A) Securing an end piece to the end of the tube furthest from the first lumen access opening;
(B) Simultaneously testing the balloon portion of the resulting catheter and substantially removing the removable preventing bond agent from the first portion of the outer surface and the first lumen access opening;
(C) Further testing the catheter capillary lumen and the balloon portion for leaks;
(D) Punching a second lumen access opening in an exterior surface of the catheter to communicate with the second lumen;
(E) Packaging the resulting balloon catheters; and
(F) Sterilizing the balloon catheters.
In certain embodiment of the present invention following the securing of a plurality of intermediate tubes 3 to the transportable pallet 24, balloon catheters are produced as follows:
(A) The pallet 24 is stopped over a first tank 33, which contains a liquid soap (Liquid Ivory Soap from Proctor & Gamble Co., Cincinnati, Ohio 45202). The soap is held at room temperature (between about 60°-80° F., for example 65°-72° F.). The dip tank 33 is raised so as to immerse the intermediate tubes 3 into the liquid soap so that the soap coats the tubes 3 up to the dashed line designated by the letter A in
(B) The pallet 24 is then automatically advanced and stopped over a second dip tank 35 which contains an aqueous solution containing a trace of a suitable wetting agent or surfactant. In an embodiment, three gallons of water is mixed with two ounces of a suitable surfactant. The surfactant will generally be less than one percent of the total volume of the solution. The second dip tank 35 is then raised so as to immerse the intermediate tubes 3 in the aqueous fluid up to the dashed line designated by the letter B in
(C) The pallet 24 is then automatically advanced and stopped over a third dip tank 37 containing water. The third dip tank 37 is then raised and the intermediate tubes are immersed in the water up to the line designated B as in the prior dipping step. The third dip tank 37 is then lowered and virtually all of the liquid soap is removed from the portion 14a of the outer surface 14 below the line designated B.
(D) The pallet 24 is then automatically advanced and stopped over a fourth dip tank 39 containing a low-solids hexamethyl disiloxane silicone rubber solution which is effective to minimize any disruption of the integrity of the liquid soap coating 38 remaining on each of the intermediate tubes proximate the portion 14c of the outer surface 14 where the balloon lumen will be created during subsequent dipping steps (the portion between the dashed lines designated A and B). The fourth tank 39 is then raised to immerse essentially the entire length of each of the intermediate tubes 3 in the silicone rubber solution. It will be appreciated that other organic solvents such as toluene, and the like may be substituted for the hexamethyl disiloxane solvent used in this example. It will also be appreciated that the dipping step can be repeated at subsequent intervals, for example long enough to permit significant solvent evaporation (prior to any subsequent dipping), to add to the thickness of the overcoat layer 42 and the balloon portion 58 of the overcoat layer 42. Further steps, involving different solutions, can also follow.
(E) Once the fourth dip tank 39 is lowered, and the uncured silicone rubber, coating portions of the outer surface 14 as well as the coating of soap 38, is allowed to dry, the pallet 24 is advanced again to a fifth dip tank 41 for example containing a different silicone rubber solution having a solids content which is higher than the solids content in the fourth dip tank 39. This step can be eliminated, but may be useful to add thickness if desired. The intermediate tubes are immersed again in the subsequent silicone rubber solution when the fifth dip tank 41 is raised. The fifth dip tank 41 is then lowered, and the silicone rubber coating the tubes 3 is allowed to dry.
(F) The pallet 24 is then automatically advanced again to a sixth dip tank 43 containing the silicone rubber/antimicrobial compounds fluid mixture described hereinabove. The tubes can be dipped a second time after allowing about 10-15 minutes for drying. The sixth dip tank 43 is then lowered and the silicone rubber/antimicrobial compounds coating the tubes 3 is allowed to dry for about 15 minutes.
(G) The pallet 24 is then advanced through a drying step followed by a heat cure step (air dried at 200° F. for 1 hour), and each completed balloon catheter 4 is then secured to an end piece, tested, provided with a fluid conduit access opening 56, packaged and sterilized.
The automated system that Applicants claim will permit completed Foley catheters 5 to be manufactured at the rate of about 1,600 catheters per hour. Because no handwork is involved, the catheters 5 produced will be consistent and of very high quality. The exterior surface 62 is smoother than hand-glued balloons, and the outside diameter of the balloon portion 58 is essentially identical to the outside diameter of other portions of the completed Foley catheters 5. In addition, by eliminating the hand labor involved in adhering the balloon portion 58 to the intermediate tube 3 in the manufacture of silicone rubber balloon catheters 4, by specifically eliminating the separate step of fabricating the balloon portion, which also requires hand labor, and by eliminating the significant impact on yield resulting from hand processing errors, the applicants' new process will permit direct production cost for silicone rubber balloon catheters of all types to be reduced by about 25-50% over the cost estimated for the prior art silicone rubber balloon catheters.
Referring now also to
Referring specifically now also to
Referring now also to
When the intermediate tubes 3′ have been secured on the support rods 26′, the pallet 24′ can be transferred from place to place, and the intermediate tubes 3′ on the pallet 24′ can be dipped in a series of baths prepared to accomplish a series of process steps. In an embodiment of the method of the present invention, the intermediate tube 3′ is made entirely of silicone rubber and is secured upon a support rod 26′ made of spring steel. The tip 20′ and the fill material 18′ of the intermediate tube 3′ shown in
The first step in the automated coating or dipping process of forming the resilient sleeve 44′ and the balloon portion 32′ of the balloon catheter 4′ (shown in
When the intermediate tubes 3′ are removed from this first bath 33a′ of removable bond preventing lubricating agent 38′, the agent or substance 38′ adheres to the outer surface 14′ of the intermediate tube 3′, and occupy the capillary lumen access opening 12′ and the capillary lumen 6′. In one embodiment the agent is petrolatum, which is heated to about 140°-160° F., for example about 150° F. At these temperatures, the petrolatum will run up into the capillary lumen 6′ through the capillary lumen access opening 12′ with the assistance of the “capillary effect”, which draws the fluid into the capillary lumen 6′ to the level of the petrolatum in the first tank 33′. As the intermediate tubes 3′ are withdrawn from the hot petrolatum, petrolatum on each tube cools and solidifies to form a semi-solid coating 38′ on the outer surface 14′ and a semi-solid filling (not shown) in the capillary lumen 6′ and the capillary lumen access opening 12′ which cooperate to plug the capillary lumen access opening 12′. In an alternate embodiment, the bond preventing agent in the first tank 33′ is liquid soap at room temperature (about 62°-74° F.). When the tubes 3 are withdrawn from the first dip tank 33, the liquid soap forms a semi-solid just as the hot petrolatum did as it cooled.
In the an embodiment of the method of the present invention, the intermediate tubes 3′ are coated when they are dipped in a first bath 33a′ which contains petrolatum which is maintained at a temperature effective to permit the petrolatum to coat the outer surface 14′ of the tube while limiting the degree to which the petrolatum runs into the smaller lumen 6′. The petrolatum will run into the first lumen access opening 12′, but, for example, will not run very far into the smaller lumen 6′. The temperature of the petrolatum in the first tank 33′ is for example maintained at about 40°-80, about 50°-70°, about 55°-65°, or about 60° C. for this purpose. As shown in
Following this step, the outer surface 14′ of the intermediate tube 3′ is stripped of the bond preventing lubricating agent 38′ up to a location proximate the dashed line designated B in
After the intermediate tubes 3′ are coated in this manner and the capillary lumen access openings 12′ are plugged with bond preventing agent 40′, the tubes 3′ are then dipped in a series of dip tanks (see
The outer release layer 61′ is then air dried for about an hour, and then cured. In order to avoid a poor bond between the release layer 61′ and the rest of the tube 3′, the release layer 61′ is coated only over the uncured silicone rubber overcoat layer 42′. In order to avoid any sagging, elongation or stretching of the resilient sleeve 44′ or the balloon portion 58′ of the balloon catheter 5′ shown in
In subsequent steps, the proximal end 30′ of the balloon catheter 5′ is secured to an end piece 46′ to form a completed Foley catheter 4′ (shown in
Referring now also to
In certain methods in accordance with the present invention, the end piece 46′ is made by a process of injection molding. In an embodiment, the proximal end 30′ of the sleeved balloon catheter 5′ is inserted into an injection molding apparatus (not shown) after the overcoat layer 42′ and the release layer 61′ have been cured. However, it will be appreciated that the end piece 46′ can be added to the intermediate tube 3′ prior to the initiation of the dipping process. A polymeric bonding composition, for example silicone rubber, is then injected into the mold (not shown) and the end piece 46′ is molded onto the proximal end 30′ of the balloon catheter 5′ to make the completed Foley catheter 4′ shown in
In order to test the integrity of the completed catheter 4′, prior to engaging the plug 50′ in the proximal capillary lumen access opening 52′ in the end piece 46′, the proximal capillary lumen access opening 52′ is slipped over a hot water nozzle (not shown), and a measured amount of a hot aqueous solution, for example water or water containing a trace of surfactant, at a temperature of between about 120°-160° F., for example about 140° F., is pumped into the capillary lumen 6′ from a standard hot water heater (not shown) by a commercially available water pump (not shown) such that the balloon portion 58′ is expanded. It will be appreciated that higher or lower temperatures can be used so long as the desired coating properties for the particular application desired can be obtained. The balloon portion 58′ of the overcoat layer 42′ is the portion of the overcoat layer 42′ which is not bonded to the outer surface 14′ of the intermediate tube 3′ proximate a balloon cavity 54′. The balloon portion 58′ of the overcoat layer 42′ cooperates with the portion 14c′ of the outer surface 14′ which remained coated with the bond preventing agent prior to the step of dipping the intermediate tube 3′ in the polymeric bonding composition, to define the balloon cavity 54′. The balloon cavity 54′ communicates with the capillary lumen 6′ via the Capillary lumen access opening 12′. When the hot water solution is pumped or injected into the capillary access lumen 6′ to test the completed catheter 4′ and the balloon portion 58′, the balloon portion 58′ and the balloon cavity 54′ are expanded. If there is a significant lack of integrity in the balloon portion 58′ it will be exposed when the water is introduced in this manner. In addition to testing the balloon portion 58′, the water solution will also remove the remaining bond preventing agent in the balloon lumen 54′ and the capillary lumen 6′ when it is removed. Although some of the bond preventing agent may come out of the capillary lumen 6′ via the proximal capillary lumen access opening 52′ during the step of curing the overcoat layer 42′, the hot aqueous solution is generally believed to remove most of the bond preventing agent, although a residue may remain.
Following the preliminary test, which relies on a visual observation to determine whether there is any lack of integrity, a further test is used to obtain further assurance that there are no leaks in the balloon portion 58. This further test is accomplished by engaging the proximal capillary lumen accessing opening 52′ to the nozzle of a commercially available leak tester (not shown). One such device is a Model No. 6510 Caps Tester from Caps Himmelstein (Hoffman Estates, Ill. 60195). Once the completed catheter 4′ is tightly secured over the nozzle, an electrical switch, such as a hand switch or, for example, a foot pedal, is used to release a measured blast of air into the capillary lumen 6′. When the air is introduced into the capillary lumen 6′ it also enters the balloon cavity 54′ via the capillary lumen access opening 12′ and inflates the balloon portion 58′ and, thereby, expands the balloon cavity 54′. The leak tester is designed to sense any loss of pressure once the balloon portion 58′ is inflated, and will given an indication, therefore, if there are any measurable leaks. After this test is completed, the completed sleeved Foley catheters 4′ that have passed all tests, are then packaged, for example in a material which breathes such as Tyvek (from DuPont), and boxed. The boxes are then sterilized with ETO (Ethylene Oxide) and then stored for shipment.
Referring now specifically to
The overcoat layer 42 of the elongated catheter 4′″ in accordance with the present invention, includes a sleeve 44′″ which encircles a sleeve cavity 45′″ which contains lubricating material 38′″. The lubricating material or substance 38′″ is effective to permit the sleeve 44′″ to slide along the outer surface 14′″ of the tube 2′″ proximate the sleeve 44′″ while in lubricated contact with the outer surface 14′″. When applied in sufficient thicknesses, the lubricating material serves to separate the soft outer sleeve 44′″ from the tube 2′″, such that the outer sleeve 44′″ provides a soft, cushioned, compliant exterior surface which can adapt and conform under slight pressures to the shape of the passageway in which it is inserted or residing. Depending on the catheter application and/or type, the amount of the lubricating substance 38′″ and the sleeve cavity 45′″ can be minimized to provide for only a limited increase in the outer diameter of the catheter proximate the outer sleeve 44′″. The outer sleeve 44′″ is coated with an outer fungicide release layer 61′″ similar to that described hereinabove. In other cases, a soft, cushioned, compliant sleeve which can adapt its shape is desirable. In these embodiments, there is a relatively thick coating of lubricant material 38′″ in the sleeve cavity 45′″ which will give the sleeve 44′″ a balloon-like feel and appearance in the exterior surface proximate the sleeve 44′″. The elongated catheter 4′″ is for example made of a flexible elastomeric material such as latex, silicone rubber or the like, most for example silicone rubber. The lubricating material or substance 38′″ is for example any biocompatible lubricating substance which is effective to permit respective polymeric surfaces to slide with respect to one another when in lubricated contact therewith. In an embodiment, the lubricating substance 38′″ is a hydrophobic oil or other petroleum based product or a water-soluble soap, detergent or the like, either of which is effective to lubricate polymeric surfaces and to generally prevent bonding thereto by other polymeric substances when coated thereby. In an embodiment, the lubricating substance 38 ′″ is petrolatum.
The first step in making an elongated catheter 4′″ in accordance with the method of the present invention is to provide a tube 2′″ having an outer surface 14′″ and an inner surface 7′″ defining a first lumen 8′″. The distal end 16′″ of the tube 2′″ is for example inserted into a molding apparatus (not shown) designed to mould a tip 20′″ on the distal end 16′″ of the tube 2′″ to form the intermediate tube 3′″ (see
After the intermediate tube 3′″ is formed from the initial tube 2′″, the outer surface is coated from the lowest portion of the tip 20′″ up to a location on the outer surface 14′″ designated by the dashed line A, as shown in
The specific procedures used to form the present elongated catheter 4′ will include steps similar to the steps used for similar purposes as described hereinabove.
In the certain embodiments, balloon and sleeve fabrication is almost completely automated. Entire sets of sleeved balloon catheters 5′ are manufactured simultaneously. The pallet 24 has 400 spring steel support rods 26 attached to a pallet in 20 rows of 20 rods, wherein each of the rods 26 is about 1 inch from each adjacent rod. Single and double lumen tubing (not shown) is for example made by extrusion processes known to those of skill in the art. The tubes 2 and 2′ are cut to length as the tubing leaves the extruder (not shown). An opening 12′ is created in the outer surface 14′ of the double lumen tubes 2′, for example with a hollow drill bit or drill tube (not shown), so as to communicate with the capillary lumen 6′ in those tubes 2′. The distal portion 6a′ of the capillary lumen 6′, located between the distal end 16′ of the tube 2′ and the capillary lumen access opening 12′, is then injected with a measured amount of a polymeric bonding composition, for example silicone rubber, so that the distal portion 6a′ is filled and sealed. A rounded tip 20′ is then formed at the distal end 16′ of the double lumen tube 2′, for example by inserting the tube 2′ in a molding device (not shown).
Referring now also to
Referring now also to
In certain embodiments of the present method, 400 of the intermediate tubes 3′ are then mounted vertically on rigid spring steel support rods 26′ on a pallet 24′ in the manner previously described. The pallet 24′ is then moved via a transporting mechanism 22 (see
The present invention may be better understood with reference to the following examples. These examples are intended to be representative of specific embodiments of the invention, and are not intended as limiting the scope of the invention.
(A) The pallet 24′ is stopped over a first tank 33′, which contains white USP petrolatum heated to about 60° C. (about 140° F.). The tank is raised so as to immerse the intermediate tubes 3′ into the petrolatum to such a depth that the petrolatum reaches the proximal end of the desired sleeve location. The dip tank 33′ is then lowered and a portion of the outer surface 14′ of the intermediate tubes 3′ are coated with petrolatum. This portion extends from the general point at which the proximal end of the resilient sleeve 44′ will begin, to the distal end 20a′ of the tip 20′ of the intermediate tube 3′. This step is repeated when it is desirable to build up the thickness of the lubricating substance and the resulting volume of the sleeve cavity so as to increase the resulting increase in the outside diameter of the particular catheter over the circumferential diameter of the conduit portion or tube 2 or 2′ of this present invention.
(B) The pallet 24′ is then automatically advanced and stopped over a second dip tank 35′ which contains white USP petrolatum heated to about 120° C. (about 250° F.). The second dip tank 35′ is raised so as to immerse the intermediate tubes 3′ into the super-heated petrolatum so that the super-heated petrolatum comes into contact with the petrolatum coating 38′ on outer surface 14′ of the intermediate tube 3′ from the prior dipping step up to a general location where a distal end of the resilient sleeve 44′ will end. The second dip tank 35′ is then lowered. This dipping step causes the coating of petrolatum from the prior dipping step to be largely removed from the portions 14a′ the outer surface 14′ below a location where the distal end of the resilient sleeve 44′ will be generally located (designated by dashed line B) to the distal end 20a′ of the tip 20′ of the intermediate tube 3′. Some residual petrolatum may remain on the outer surface 14′ of the intermediate tube 3′ in this area of the outer surface 14′. However, most of the petrolatum is removed.
(C) The pallet 24′ is then automatically advanced and stopped over a third dip tank 37′ containing mineral spirits heated to about 200° F. The third dip tank 37′ is then raised so as to immerse the intermediate tubes 3′ into the mineral spirits to the same depth as they were immersed in the super-heated petrolatum in the second dip tank 35′. The tank 37′ is then lowered and all but a trace amount of the petrolatum is removed from the outer surface 14′ located generally below the dashed line B, which will eventually be proximate the sleeve 44′.
(D) The pallet 24′ is then automatically advanced and stopped over a fourth dip tank 40′ containing a volatile organic solvent such as toluene, trichloromethane or the like. The fourth tank 40′ is then raised to immerse the intermediate catheters 3 to the same depth as previously immersed in the second and third tanks 35′ and 37+, thereby removing essentially all traces of the petrolatum from this portion of the outer surface 14′. The intermediate catheter tube 3′ now has a band 38′ of semi-solid petrolatum located around the axial circumference of the intermediate tube 3′ in the location where the sleeve cavity 45′ will be created.
(E) The pallet 24′ is then stopped over a fifth, sixth, seventh and eighth dip tank, 41′, 43′, 51′ and 53′, respectively, where the steps enumerated in steps A, B, C, and D, respectively, are repeated with the following variation. When the pallet 24′ is stopped over the fifth dip tank 41′, the intermediate tubes 3′ are immersed only up to a location proximate the dashed line designated C as shown in
(F) After the last of these dip tanks (53′) is lowered, the pallet 24′ is automatically advanced to a ninth dip tank 55′ containing a low-solids silicone rubber/solvent dispersion which is effective to minimize any disruption of the integrity of the petrolatum coatings 38′ or 40′ remaining on the intermediate tube 3′ proximate the portions 14e′ and 14c′ of the outer surface 14′ where the sleeve cavity 45′ balloon cavity 54′ will be created during subsequent dipping steps. The ninth tank 51′ is then raised to immerse the intermediate tube 3′ in the solution up to a location above the dashed line designated in A in
(G) The pallet 24′ is then advanced through a drying area where solvents are allowed to evaporate, and then through a two port (liquid/hot air) heat cure step, where the sleeved balloon catheters 5′ formed by this process are cured, first in a hot liquid bath at 160° F. for 15 minutes, and then in hot air (200° F.), or at a temperature just below the boiling point of any solvent used in any of the silicone rubber dip dispersions, for an hour. For toluene this temperature is about 200° F.
(H After the heat cure, the sleeved balloon catheters 5′ are allowed to cool and are then removed from the support rods 26′. The proximal ends 30′ of each of the balloon catheters 4 is then inserted into an injection molding apparatus (not shown), which forms the end piece 46′ of the completed sleeved Foley catheter 4′.
(I) The completed Foley catheters 5 are then finished by punching a fluid conduit access opening 56′ in the exterior surface 61′ such that it communicates with the fluid conduit lumen 8′ in a location below or distal to the balloon portion 58′ of the overcoat layer 42′.
(J) The completed Foley catheters 4′ are then sent through the test sequence described hereinabove, during which the balloon portion 58′ of each completed Foley catheter 4′ is inflated and the petrolatum band 40′ within the balloon cavity 54′ is largely removed. Referring now also to
(A) Providing a tube having an outer surface and first and second lumens;
(B) Cutting the tube to a desired length;
(C) Creating a first lumen access opening in the outer surface to communicate with the first lumen;
(D) Filling the first lumen with a polymeric bonding composition up to the first lumen access opening from an end nearest the first lumen access opening'
(E) Sealing the end of the tube nearest the first lumen access opening; and
(F) Securing the tube to a movable pallet.
These steps are followed by the following steps:
(A) Coating a first portion of the outer surface and plugging the first lumen access opening with a removable bond preventing lubricating agent;
(B) Stripping the coating of removable bond preventing lubricating agent away from a second portion of the outer surface adjacent to the first portion;
(C) Simultaneously coating a third portion of the outer surface adjacent to the second portion thereof and plugging the first lumen access opening with a removable bond preventing agent;
(D) Stripping the coating of removable bond preventing agent away from a fourth portion of the outer surface adjacent to and below the third portion thereof;
(E) Coating the outer surface and the remaining coating of removable bond preventing agent with an overcoat layer of a suitable film forming polymeric bonding composition;
(F) Coating the overcoat layer with a silicone rubber/antimicrobial coating mixture to form an outer antimicrobial release layer;
(G) Air drying outer antimicrobial release layer; and
(H) Curing the overcoat layer.
Following those steps, methods of the present invention include the following steps:
(A) Securing an end piece to the end of the tube furthest from the first lumen access opening;
(B) Simultaneously testing the balloon portion of the resulting catheter and substantially removing the removable preventing bond agent from the first portion of the outer surface and the first lumen access opening;
(C) Further testing the catheter capillary lumen and the balloon portion for leaks;
(D) Punching a second lumen access opening in an exterior surface of the catheter to communicate with the second lumen;
(E) Packaging the resulting sleeved Foley catheters; and
(F) Sterilizing the sleeved Foley catheters.
In another embodiment of the present invention, following the securing of a plurality of intermediate tubes 3′ to the transportable pallet 24′, balloon catheters are produced as follows:
(A) The pallet 24′ is stopped over a first tank 33′, which contains white USP petrolatum heated to about 60° C. That tank 33′ is then raised so as to immerse the intermediate tubes 3′ into the petrolatum to such a depth that the petrolatum reaches the proximal end of the desired resilient sleeve location proximate the dashed line designated A in
(B) The steps outlined in paragraphs B, C and D of Example I presented hereinabove, are then followed generally as outlined in Example I.
(C) The pallet 24′ is then stopped over a fifth dip tank 41′, which contains a liquid soap (Liquid Ivory Soap from Proctor & Gamble Co., Cincinnati, Ohio 45202). The soap is held at room temperature (between about 6°-80° F., for example 65°-72° F.). The fifth dip tank 41′ is raised so as to immerse the intermediate tubes 3′ into the liquid soap so that the soap coats the tubes 3′ up to the dashed line designated by the letter C in
(D) The pallet 24 is then automatically advanced and stopped over a sixth dip tank 43′ which contains an aqueous solution containing a trace of a suitable wetting agent or surfactant. In an embodiment, three gallons of water is mixed with two ounces of a suitable surfactant. The surfactant will generally be less than one percent of the total volume of the solution. A sixth dip tank 43′ is then raised so as to immerse the intermediate tubes 3′ in the aqueous fluid up to the dashed line designated by the letter D in
(E) The pallet 24′ is then automatically advanced and stopped over a seventh dip tank 51′ containing water. The seventh dip tank 51′ is then raised and the intermediate tubes 3′ are immersed in the water up to the line designated D as in the prior dipping step. The seventh dip tank 51′ is then lowered and virtually all of the liquid soap is removed from the portion 14a′ of the outer surface 14′ below the line designated D.
(F) The pallet 24′ is then automatically advanced and stopped over a eighth dip tank 53′ containing a low-solids silicone rubber/solvent dispersion which is effective to minimize any disruption of the integrity of the liquid soap coating 40′ remaining on each of the intermediate tubes proximate the portion 14c′ of the outer surface 14′ where the balloon cavity 54 will be created during subsequent dipping steps (the portion between the dashed lines designated C and D). The eighth tank 53′ is then raised to immerse intermediate tubes 3′ in the silicone rubber dispersion. It will be appreciated that any suitable solvent for providing a suitable dispersion of silicone rubber and coating the particular lubricating agent may be used. It is also believed to be possible to use aqueous solvents. It will also be appreciated that this step can be repeated at subsequent intervals, for example long enough to permit significant solvent evaporation, to add to the thickness of the overcoat layer 42′ and the balloon portion 58′ of the overcoat layer 42′. However, further steps, involving different solutions can also follow.
(G) The fourth dip tank 39′ is then lowered and the silicone rubber, coating portions of the outer surface 14′ as well as the coating of petrolatum 38′ and the coating of soap 40′, is allowed to dry. The pallet 24′ is then advanced again to a ninth dip tank 55′ containing a different silicone rubber dispersions having a solids content which is higher than the solids content in the eighth dip tank 53′. The intermediate tubes 31′ are immersed again in the subsequent silicone rubber dispersion when the ninth dip tank 55′ is raised. The ninth dip tank 55′ is then lowered, and the silicone rubber, coating the tubes 3′, is allowed to dry.
(H) The pallet 24′ is then automatically advanced again to a tenth dip tank 53 containing a silicone rubber/nitrofuran/paraben compound fluid mixture 17′ including a silicone rubber and silicone fluid in trichloroethane, mixed with a nitrofuran compound, for example with furazone and a paraben antifungal, for example paraben particles having a mean particle diameter of 100 microns or less. The tubes 3′ are dipped again as before and the tenth dip tank 51′ is then lowered and the silicone rubber coating the tubes 3′ is allowed to dry.
(G) The pallet 24′ is then advanced through a drying step followed by a two-part (liquid/hot air) heat cure step, and each completed sleeved balloon catheter 5′ is then secured to an end piece 46′, tested, provided with a fluid conduit access opening 56′, packaged and sterilized.
The automated system that Applicants claim will permit completed sleeved Foley catheters 4′ to be manufactured at the rate of about 1,600 catheters per hour. Because virtually no handwork is involved in the balloon and sleeve construction, the catheters 4′ produced will be consistent and of very high quality. The exterior surface 62′ is smoother than hand-glued balloons, and the outside diameter of the balloon portion 58′ is essentially identical to the outside diameter of other portions of the completed Foley catheters 4′. It will be appreciated that larger outside diameter balloon portions are undesirable since they are somewhat more difficult to insert and withdraw, and cause additional trauma upon withdrawal. In addition, by eliminating the hand labor involved in adhering the balloon portion 58′ to the intermediate tube 3′ in the manufacture of silicone rubber balloon catheters 5′, by specifically eliminating the separate step of fabricating the balloon portion, which also requires hand labor, and by eliminating the significant impact on yield resulting from hand processing errors, the applicants' new process will permit direct production cost for silicone rubber balloon catheters of all types to be reduced by about 25-50% over the cost estimated for the prior art silicone rubber balloon catheters.
It should be noted that, as used in this specification and the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the content clearly dictates otherwise. Thus, for example, reference to a composition containing “a compound” includes a mixture of two or more compounds. It should also be noted that the term “or” is generally employed in its sense including “and/or” unless the content clearly dictates otherwise.
It should also be noted that, as used in this specification and the appended claims, the term “configured” describes a system, apparatus, or other structure that is constructed or configured to perform a particular task or adopt a particular configuration. The term “configured” can be used interchangeably with other similar phrases such as arranged and configured, constructed and arranged, adapted and configured, adapted, constructed, manufactured and arranged, and the like.
All publications and patent applications in this specification are indicative of the level of ordinary skill in the art to which this invention pertains.
The invention has been described with reference to various specific and preferred embodiments and techniques. However, it should be understood that many variations and modifications may be made while remaining within the spirit and scope of the invention.
This application claims benefit of U.S. Provisional Application No. 61/568,290, filed Dec. 8, 2011, which application is incorporated herein by reference.
Number | Date | Country | |
---|---|---|---|
61568290 | Dec 2011 | US |